Aveanna healthcare sees significant stock sales by major shareholder

Published 16/05/2025, 20:46
Aveanna healthcare sees significant stock sales by major shareholder

J.H. Whitney Equity Partners VII, LLC, a major shareholder of Aveanna Healthcare Holdings , Inc. (NASDAQ:AVAH), recently executed a series of stock sales totaling $542,540. The transactions, which occurred on May 14 and May 15, 2025, involved the sale of shares at prices ranging from $5.88 to $5.89 per share. The sales come as AVAH, currently valued at $1.17 billion, trades near its 52-week high of $6.19, having delivered an impressive 126% return over the past year. According to InvestingPro analysis, the stock is currently fairly valued.

According to the filings, J.H. Whitney Equity Partners VII, LLC, through its affiliates, disposed of shares across multiple transactions. On May 14, sales included 29,296 shares and 14,637 shares, while on May 15, transactions included 30,340 shares and 15,158 shares. These sales were conducted under a Rule 10b5-1 trading plan, which had been adopted by the involved entities in December 2024. InvestingPro data shows the stock has maintained strong momentum, with an 11% gain in the past week alone. Subscribers can access 10+ additional ProTips and comprehensive analysis in the Pro Research Report.

The transactions leave the shareholder with a significant number of shares still under indirect ownership through various affiliated entities. The sales were part of a pre-arranged trading plan, indicating a strategic approach to stock management by the shareholder. With a beta of 2.01, AVAH shows higher volatility than the broader market, and the company has demonstrated solid revenue growth of 9% over the last twelve months.

In other recent news, Aveanna Healthcare Holdings Inc. reported its first-quarter 2025 financial results, which exceeded market expectations. The company achieved earnings per share of $0.10, surpassing the anticipated loss of $0.0014, and generated revenue of $559 million, outperforming the forecast of $513.7 million. Aveanna projects its annual revenue to exceed $2.15 billion, supported by strategic acquisitions and payer agreements. Additionally, Aveanna announced positive outcomes from its 2025 Annual Meeting of Stockholders, with the election of directors and the ratification of Ernst & Young LLP as the company’s independent auditor.

The company is also focused on enhancing its growth through strategic partnerships and cost efficiencies, as highlighted in its earnings call. Aveanna’s adjusted EBITDA saw a significant year-over-year increase of 93.1%, reaching $67.4 million. The company is actively working on expanding its preferred payer agreements, which accounted for approximately 54% of its total Private Duty Services volumes. Furthermore, Aveanna is making progress with its acquisition of ThriveSkilled Pediatrics, which is expected to close soon, enhancing its strategic position in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.